Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical and Quantitative Research

China Health Care - Allocation Boom: Wuxi Biologics/Jinyu Bio-Tech/Hangzhou Tigermed Top Picks

Wuxi Biologics Placement - Biggest Deal Size at Launch, Well Ahead of Lock-Up Expiry

Wuxi Biologics Placement - This Time It's Different

WuXi Biologics Placement: Pushing the Limits

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical Analysis

<p>Health Care remains one of our favorite Sector overweights, both globally (ex-US) and in Greater China. We believe WuXi Biologics offers a timely opportunity to take advantage of what we expect are higher prices ahead for this biotechnology growth stock. The fundamental story is easy to see, as the company has delivered top line annual sales growth of over 60% for the past four years coupled with an EPS CAGR of 129% over the past three years (FactSet). Of course, what is most important to us is that the price of the stock is confirming the fundamental story. Buy this breakout, and secondarily buy any pullback toward 97 HK$ base support (if applicable). </p>

Health Care remains one of our favorite Sector overweights, both globally (ex-US) and in Greater China. We believe WuXi Biologics offers a timely opportunity to take advantage of what we expect are higher prices ahead for this biotechnology growth stock. The fundamental story is easy to see, as the company has delivered top line annual sales growth of over 60% for the past four years coupled with an EPS CAGR of 129% over the past three years (FactSet). Of course, what is most important to us is that the price of the stock is confirming the fundamental story. Buy this breakout, and secondarily buy any pullback toward 97 HK$ base support (if applicable). 

Company Spotlight: Buy WuXi Biologics Inc. (2269-HK)